Nivolumab + Relatlimab FDC

DRUG2 trials

Sponsors

Stanford University, Bristol-Myers Squibb

Conditions

Brain MetastasesMelanomaSolid Tumors

Phase 2

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

RecruitingNCT06712927

Stanford UniversityBrain Metastases, Melanoma

Start: 2025-08-06End: 2030-02-28Target: 60Updated: 2025-09-08

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Not yet recruitingNCT07492680

Bristol-Myers SquibbSolid Tumors

Start: 2026-07-17End: 2032-05-20Target: 260Updated: 2026-03-25